VDP-164 VitaDAO Funding Proposal: $500K Loan to Advance VITARNA Through Non-GLP Toxicology Toward 2026 IND Submission

[alexdobrin]

Executive Summary

VitaDAO proposes a $500,000 loan, recovered through a further fundraise, to VITARNA/ArtanBIO to optimize a GMP manufacturing process and advance ARTAN-102, their lead AAV9 gene therapy for aging, into non-GLP toxicology studies in non-human primates. According to company leadership, this funding will enable non-GLP toxicology studies by the end of 2025, followed by IND-enabling studies throughout 2026, with clinical trials targeted for late 2026 or early 2027.

Led by CEO Anthony Schwartz and CSO Michael Torres, ARTAN Bio focuses on arginine mutations, specifically the CGA codon, common in proteins related to DNA damage, neurodegeneration, and tumor suppressors. Their approach aims to restore protein levels of these age-related proteins.

Recent Progress & Achievements by VITARNA

ARTAN Bio (VitaRNA) and Syenex Team Up to Accelerate Next-Generation Anti-Aging Therapy

Strategic collaboration that could significantly speed up the development of ARTAN-102, a pioneering gene therapy designed to reverse epigenetic changes associated with aging. This partnership brings together ARTAN’s innovative codon suppressor platform with Syenex’s VivoCell delivery technology.

Jay Rosanelli, CEO of Syenex, emphasized the potential impact: “ARTAN Bio has generated strong preclinical data on the therapeutic potential of their lead drug candidate, ARTAN-102. By combining their codon suppressor platform with our VivoCell Platform, we aim to shorten development timelines and unlock treatment options for aging and age-related disease.”

September 2025: GMP Manufacturing Process Development at Lonza

ArtanBio leadership performed a site visit at Lonza. They are currently optimizing larg-scale manufacturing conditions to support the material generation for the non-GLP toxicology study in non-human primates.

June 2025: First In Vivo Success

ARTAN-102 (our gene therapy for age-related mutations) demonstrated zero adverse effects. It achieved broad biodistribution, reaching multiple organs, including the brain, marking a critical safety milestone and highlighting the AAV9 delivery platform’s extensive biodistribution capability.

October 2024: Lead Candidate Validation

The team has successfully identified and validated two promising lead candidates from their initial screening of 15 candidate oligos, with successful in vitro testing showing drug prototypes suppress arginine nonsense mutations in cancer cell lines with nonsense mutations in P53. The innovative approach focuses on suppressing arginine nonsense mutations, particularly the CGA codon, which plays a crucial role in proteins associated with DNA damage, neurodegeneration, and tumor suppression.

Community Support & Tokenization Success

VitaDAO has successfully tokenized the IP-NFT, Artan Bio, and raised $300k. This funding will support advancing ARTAN Bio R&D. The tokenization creates a unique community-driven model

Scientific Foundation & Current Status

ARTAN-102 is an engineered suppressor tRNA delivered via AAV9 that reads through premature termination codons, restoring full-length protein synthesis. With the recent in vivo success showing safety across all major organs, including brain penetration, the program has achieved significant technical validation beyond initial in vitro proof-of-concept. The established qPCR and protein readout assays provide robust analytical methods for both batch release and future clinical development.

Development Timeline & Critical Milestones

The immediate funding addresses a critical juncture in development. Manufacturing activities at Lonza require immediate capital to maintain the current production slot, with any delay resulting in a 6-month setback that would cascade through the entire development timeline.

By securing this funding now, VITARNA can complete manufacturing and analytical validation in Q3-Q4 2025, followed by comprehensive non-GLP toxicology studies by year-end. These studies will include dose-range finding in rodents, biodistribution analysis via qPCR, and complete PK/PD characterization that will inform the design of the monkey GLP studies planned for early 2026.

The path to clinical trials is clearly defined: following non-GLP completion, the company will require approximately $1.5-2M in additional funding to conduct GLP toxicology in non-human primates (early 2026), complete the full IND-enabling package throughout 2026, and submit to regulators for clinical trial authorization. The pre-IND meeting is planned for Q1 2026, allowing incorporation of regulatory feedback into the GLP study design. This positions the company for IND submission in late 2026 and first-in-human trials by early 2027.

Strategic Expansion & UAE Initiative

VITARNA is exploring strategic opportunities in the UAE that could accelerate development and provide early commercialization pathways. The UAE’s progressive regulatory environment for biotechnology and gene therapy, combined with streamlined clinical trial processes, offers potential for faster proof-of-concept studies.

Market Opportunity & Competitive Positioning

Funding Allocation & Use of Proceeds

Motivation

The team’s momentum must be maintained to achieve the aggressive but achievable timeline of non-GLP by end-2025, monkey studies in early 2026, IND submission in late 2026, and clinical trials in 2027. As part of VitaDAO’s strategy to double down and accelerate its highest-potential projects, this bridge funding ensures VITARNA maintains its first-mover advantage in codon suppression therapy while competing programs advance rapidly, making immediate action critical.

Conclusion

This $500K bridge financing enables VITARNA/ArtanBIO to build on their remarkable recent progress—including successful in vivo demonstration with zero adverse effects and broad organ distribution—to complete critical near-term milestones. Funds comprehensive non-GLP toxicology studies, and positions the company for monkey GLP studies and subsequent clinical development. With clear line-of-sight to clinical trials within 18-24 months, strong community support through successful tokenization, and multiple value inflection points along the way

Vote: Approve $500,000 loan recovered in a further fundraise to VITARNA/ArtanBIO with immediate deployment to secure manufacturing and achieve end-of-2025 non-GLP toxicology milestone.

• Agree
• Revisions Requested (Detail in Comments)
• Disagree

After this poll, a senior review was carried out, the results follow.

Senior Review Digest - Quantitative

Below is the average scores out of 5 per category from 4 reviewers, including two biotech entrepreneurs, one biotech VC and one pharma VC. Two of the the reviewers were previously scientists.

Average Scores

• Team Expertise: 3
• Feasibility & Data: 2.5
• Commercial Potential & Impact: 2.0
• Novelty & Market Advantage: 3.0
• IP Defensibility: 3.5
• Relevance to Longevity: 2.5
• Deal Terms: 2.5
• Overall Conviction Score 2.3 (for reference, the average score of past funded projects is 3.7)

Senior Review Digest - Qualitative

Two reviewers think that this project is a moonshot, one that it a typical profile, one did not answer.

Each reviewer was asked whether they would endorse the project, below are their answers.

Reviewer 1
I would endorse VitaDAO funding only after the company will provide more robust data on delivery, administration route, efficacy and IP.

Reviewer 2
I would endorse VitaDAO funding this project conditionally and in principle, contingent on the generation of a rigorous preclinical package that establishes mechanism of action, causal efficacy, and safety, and on a clear narrowing of the initial indication to a regulator-acceptable post-chemotherapy condition with defined functional endpoints. The project represents a genuinely novel and intellectually bold attempt to address mutation-driven functional decline, an underexplored but potentially important axis in longevity biology. While the platform ambition is high-risk and currently insufficiently de-risked for broad aging claims, the post-chemotherapy setting offers a credible and disciplined path to near-term proof-of-concept; success there would generate meaningful scientific validation, translational leverage, and strategic optionality—even if clear entry point indication and clinical development plans need to be defined and a broader healthspan or aging applications ultimately require substantial additional validation.

Reviewer 3
I would not endorse VitaDAO funding the project. While the technology is innovative and the team has demonstrated the ability to advance early preclinical development, there is insufficient evidence that the proposed mechanism addresses a meaningful or prevalent driver of aging or post-chemotherapy decline. Also, promiscuous readthrough just doesn’t feel like the technology of the future when we’re in the midst of a gene editing revolution.

Reviewer 4
No, and putting this in patients prior to showing efficacy and long term safety is extremely irresponsible and would harm VitaDAO significantly. The team should try to raise capital from biotech VCs to proceed with the efficacy and long-term safety studies on the construct. Perhaps there’s a pivot to genetic conditions where this arginine mutation is more strongly correlated with the disease. It has not been shown to be a driver of aging. That’s the basic minimum.

As next step, two of the reviewers recommended to follow-up with applicant for more information, while he other two recommended to deny outright with constructive feedback.

[kabloom.eth]

I’m in favor – VITARNA is a solid project, worth supporting, and a good use of VitaDAO resources. In.

[bowtiedshrike]

Is this an interest-free loan, or what is the rate?

The fundraise at a later date assumes VitaRNA is successful. If unsuccessful, this loan will default. Is there any collateral that Artan is putting up? How much VitaRNA does VitaDAO hold?

The proposed work is all safety/tox. Are there any additional efficacy studies in here?

[SimiKol]

Strong support. Been following VitaRNA since the initial IPT and the execution has been consistent. The Abu Dhabi trials make sense strategically!

[alexdobrin]

Interest-free loan with repayment triggered by future fundraising success. VitaDAO holds 56% of VitaRNA supply—fully aligned with project outcomes.

[mykalt45]

I’d love to hear what efficacy studies you have in mind (genuinely). We’re working on CHIP models. Importantly, we’ve got buy in from UAE to get into patients once we have GLP tox. That’s been our key focus. With that data in hand we can continue to explore efficacy models while going after the big prize…testing in humans. I know you follow me on Twitter, so I assume you’ve seen the papers I’ve been sharing related to biology and the MOA we’re working on.

[SB23]

1. VCs will not pay back a loan out of future financings – we’d only get paid back at an exit event. If I’m an early stage VC and there’s a 5M financing round, there’s no way I would let 10% of that round get paid out to earlier investors. They would simply convert that debt to equity if a financing would occur at all (unlikely given the level of validation for this project).

Agree with Bowtiedshrike – there appears to be no efficacy data, or long-term safety data either.

Examples:

1. In vitro – easy: Treat primary cells with the Artan candidate drug, expand the cells over a few months to assess differential mutation rate. This is an experiment that any lab could perform, and would address the key question of whether the drug actually affects mutation or arginine opal mutation read-through beyond a single locus (p53 in a single cell line bearing this mutation).

Does it work in WT cells, not a contrived cell line where p53 is already mutated?

Also, does it ameliorate the mutation at the hundreds or thousands of other genes of interest? This can be performed by sequencing the cells some period of time after the drug has been administered, it’s not rocket science.

2. In vivo: dose mice with chemo, administer the Artan candidate before, during, and after. Does it reduce mutations, cancer recurrence / enhance survival?

Part 2: dose wild type mice – does it extend lifespan? Mice mostly die from cancer, so mice are ‘easy mode’ for this MoA – they’re uniquely sensitive to geroprotection by reducing mutation or preventing cancer.

These are the basic minima for the efficacy studies anyone would ask for prior to giving to patients.

3. What’s the proposed clinical trial design? Endpoints, patient numbers, recruitment criteria?

The trial design mentioned (dosing to patients post-chemo) doesn’t make sense – chemo patients have compromised immune systems and their doctors won’t be eager to enroll them in a study with an unproven viral gene therapy, with no demonstration of improved outcomes in even a single cancer model.

AAV9 is not safe enough for prophylactic dosing and will never be useful as a longevity therapeutic. AAVs are used for life-threatening genetic diseases because those patients can accept the risks of side effects. Non-viral vectors are a more promising solution to the gene therapy delivery problem.

[SB23]

I met recently with the Abu Dhabi regulators also, they’re fairly sophisticated, and would not allow patients to receive an experimental gene therapy with a product lacking any in vivo efficacy data, such as a chemotherapy model. Even if you could convince the regulators, you’d next need to convince doctors and patients. When they ask what’s the evidence this would improve their outcomes post chemo, what data support this?

[mykalt45]

I am not sure what your conversations were like, but I spoke with Sharukh with Alex D, Paul K, and Aaron W in the room where we aligned on a plan.

I don’t disagree with more efficacy studies, but if I prioritized proving something in mice or cells, it would take forever to get to the clinic. Safety is the top priority for regulators.

My first company has 2 drugs in the clinic, my current company in which I’m the CEO will be in the clinic this year after founding the company less than 3 years ago (having raised $30M).

It’s interesting to see the critiques when this project was first launched through VitaDAO and how we’ve addressed or made moot many of them.

[bowtiedshrike]

The X TL shows me some stuff, but they also play games with which things they show.

Given that you’ve chosen post-chemo aging for proof-of-concept, it seems straightforward to do some efficacy. Give mice toxic doses of cis-platin or whatever major chemo you plan to do in humans (ie balancing the most common chemo used in UAE with nastiest side effects you plan to fix) , then dose with ARTAN-102 or empty AAV9, and read out your aging phenotypes. The mouse experiment itself could be done with wild type mice and however long you think it will need to show efficacy. Permutations could be progerid mice to help juice the phenotype, and adding the closest cancer model back in. Like your favorite 14 or 28 day cancer model that you kill with the chemo first. But those permutations may not be needed.

For choosing phenotypes, Pump.Science is running Open Field Maze for gait speed (@benji can hook you up with the CRO). Could pair that with either something like ATAC-seq, transcriptomics or whatever your favorite non-biased assay would be, and doing histopathology of the chemo damage. Would also give more safety data in a preclinical model.

The other option is to either jump on the ‘organ-on-a-chip’ fad, or grow some human iPSCs into neurons, poison them with cis-platin or whatever, treat with the drug, and measure viability, markers and function. Or if it works in a general model of senescent fibroblasts, which you may have had some data in before?

While I agree that safety data are paramount, as sebastian points out, vector can drive a lot of it. That’s where some sort of efficacy will tell you if it’s worth switching up the delivery method if there is some unexpected tox or problems with AAV9.

[SB23]

My friend, you have not addressed any of the critiques from when the project was launched.

1. Is there longevity evidence (slowing aging in any model organism whatsoever) – Nothing
2. Efficacy in any animal models of disease – nothing
3. Safety – not just the acute, short term safety from AAV exposure – but the long-term safety of this particular construct, and in multiple species. This is what regulators will want to see. The tox profile of AAV is known (and not suitable for preventive therapy for longevity) – but the long-term side effects of this particular cargo are not known.

Do you have any written documentation from the Abu Dhabi regulator on what they specifically want to see to allow IND filing? I met with them also, they absolutely will require efficacy or long term safety data in at least one animal model.

You agree with ”more” efficacy studies? There aren’t any efficacy studies yet. There’s a single Western blot cell culture experiment on a single protein which has little to do with the hypothesis about reducing instability across the entire genome.

You’re making logical fallacy called an ‘appeal to authority’ instead of responding with data or addressing the arguments. I also co-founded a company with 2 drugs in the clinic. So what? We need to run the actual experiments to test the hypothesis and you have not done that.

Can’t do GMP manufacturing or enroll a clinical trial until there’s some reason to believe the drug would work in the disease of interest, and the safety profile is known (not just AAV, but the cargo itself which is the novel aspect).

Agree w Shrike, those are the basic minimum experiments that any journal reviewer would require, much less a govt regulator who would consider dosing in humans. Perhaps the UAE regulator assumed you have that data already, as any IND would require this basic minimum of box checking.

[roneylaurent]

I’ve been following the VDP-164 discussions closely, and I’m honestly impressed by the level of rigor here. The detailed points raised by @SB23 regarding efficacy benchmarks and the IND path are a perfect example of why VitaDAO’s governance is so respected—it shows how seriously we take our mission and our treasury. This kind of healthy friction is exactly what keeps us on the right track!

As we consider such a significant $500k commitment, I’ve been thinking about how we can share this same level of confidence with those outside our core technical circles. Sometimes, the ‘why’ and ‘how’ behind our complex risk management can get a bit lost in translation for the broader community and potential partners.

I believe we have a great opportunity to turn this complexity into a strength. By collaborating with the Web3 Pod and Community WG, we could perhaps distill these IND strategies into a friendly ‘High-Transparency Series.’ The idea wouldn’t be to create ‘hype,’ but to make our rigorous evaluation process as clear to the world as it is to us here in the forum.

I’d love to hear your thoughts on this:

• Do you feel our current technical depth is reaching the wider community in a way that’s easy to understand?
• Would seeing more accessible (but still rigorous) deep-dives on major votes like this help you feel even more connected to our governance?

I’m more than happy to help the team brainstorm ways to make our scientific rigor one of our best tools for growth and community confidence!

[DAOOpsLayer]

Governance & Execution Analysis VDP-164 (ArtanBIO / VITARNA)

From an execution and governance perspective, I present a structured assessment of the proposal in light of established practices in biotech financing and pre-IND development.

The objective is not to slow execution, but to align funding with oversight mechanisms consistent with institutional standards observed in advanced preclinical programs.

From the standpoint of DAOOps (Execution Intelligence layer), I have identified several areas where a structured conversation could strengthen alignment between the team and the community, increasing predictability on the path toward IND-2026.

1. Alignment Between Exploratory Data and IND-Enabling Studies

The June 2025 in vivo data is encouraging.

However, within the typical FDA regulatory framework, exploratory data and non-GLP toxicology studies serve distinct functions on the path to IND submission.

Clarifying whether the June dataset directly informs the design of the proposed non-GLP study or represents a separate proof-of-concept stage would help align expectations with standard pre-IND regulatory pathways.

Reference: FDA Pre-IND Consultation Program and ICH M3(R2) guidelines.

2. Regulatory Strategy and Jurisdictional Transferability

The proposal references clinical discussions in Abu Dhabi alongside preparation for a US IND submission in 2026.

Clarifying whether Abu Dhabi represents a parallel validation path, a phased strategy, or a jurisdiction-specific approach would reduce regulatory ambiguity.

A simple mapping in the format:

Study → Jurisdiction → Regulatory Objective

would increase strategic visibility and capital efficiency.

Reference: ICH harmonization principles and regulatory bridging requirements.

3. Runway Visibility and Capital Allocation

In early-stage biotech, institutional evaluations typically consider:

• Current cash position

• Monthly burn rate

• Estimated post-financing runway

• Capital required to reach the next value inflection point

Providing this information would allow the community to more accurately assess the sufficiency of the requested $500k loan.

4. Retrospective Transparency

Considering the previously received $391,300, a structured retrospective allocation report, ideally developed collaboratively, would strengthen institutional clarity.

This is not a matter of distrust, but alignment with standard governance practices in venture-backed biotech.

5. Structured Scientific Review

If appropriate, enabling structured review of data by members of the Longevity Working Group or independent experts could function as a scientific checkpoint similar to an informal Scientific Advisory Board.

This would enhance credibility and prepare the project for future funding rounds.

6. Lightweight Oversight Mechanisms

Capital-intensive preclinical programs frequently adopt:

• Structured periodic reporting

• Advisory checkpoints

• Approval thresholds for significant expenditures

Introducing a lightweight collaborative governance layer could enhance predictability without creating operational friction.

7. Milestone-Linked Disbursement

Tranche-based disbursement structures are common practice in biotech financing.

Examples of objective triggers include:

• CRO contract execution

• Completion of dose-ranging study

• Interim toxicology report

• Final study report

Implementing a system with objective release criteria could reduce capital exposure while increasing predictability. If the community finds it useful, I am willing to collaborate in modeling such a structure together with the team.

Final Consideration:

As VitaDAO increases the scale of capital allocation, it is natural for its governance mechanisms to evolve toward institutional biotech standards.

By strengthening financial transparency, regulatory clarity and milestone structure, we create conditions for funding to flow with greater predictability, protecting collective capital and increasing confidence on the path toward IND-2026.

I remain available to collaborate in formalizing reporting templates or execution frameworks if the community sees value in institutionalizing these mechanisms.

[Paolo]

The proposal has just been edited to include the results of the senior review.

[mykalt45]

Why did Paolo just post a qualitative summary of reviews and ask us to reply to reviewers and not post our responses? Seems unfair to do it that way and not in the spirit of desci. I’d suggest to post links to the reviewer doc we were sent to respond to and then a link to our response document for full transparency.

[aschwartzphd]

Totally agree. The community should be able to analyze the reviews themselves rather than rely solely on 5 anonymous people whose identities no one actually knows or their “real-world” credentials.

[alexdobrin]

This followed the same format we used for previous proposals. Your points are noted — we’ll reach out to discuss them further and are open to sharing more detail.